Right now, there are many stocks well off their recent highs. As a result, I’m seeing quite a few attractive investment opportunities.
Here, I’m going to highlight two stocks I’ve snapped up for my ISA in the last few weeks. Both have taken a big hit recently and I see the potential for a rebound.
A buying opportunity
First up is Ergomed (LSE: ERGO). It’s an under-the-radar, founder-led company that provides specialised services to the pharma industry. Operating in over 100 countries, it offers solutions to project management (for drug trials, etc), clinical monitoring, regulatory affairs, and more.
Passive income stocks: our picks
Do you like the idea of dividend income?
The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?
If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…
Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.
What’s more, today we’re giving away one of these stock picks, absolutely free!
Ergomed’s share price has come down from near 1,400p to around 1,000p since the start of December and I see a lot of appeal in the stock after the fall.
This is a healthcare company that has a fair bit of momentum right now. Last year, the group generated revenue of £145.3m, up 22.5% year on year. And at the end of 2022, the group’s order book was sitting at a £295m record high.
As we look ahead to 2023, demand for our services is high.
Dr Miroslav Reljanović, Ergomed Executive Chairman
The risk here is that funding for biotech customers could dry up if financial conditions continue to tighten. This could impact the stock – which currently has a price-to-earnings (P/E) ratio of about 22 – in the short term.
Taking a long-term view however, I’m confident in the growth story. Over the next decade, the global drug discovery market is projected to grow at around 9% per year.
Huge growth potential
Another stock I bought was Airbnb (NASDAQ: ABNB), which is listed in the US. It operates the world’s largest home rental platform.
There’s a lot to like about this well-known company from an investment perspective, in my view. It has a great product/service for a start. I was reminded of this when I recently took a trip to Australia. Through Airbnb, I was able to find some top-notch accommodation.
Secondly, it has a very powerful brand, so powerful that it has even become a verb. This is a huge competitive advantage.
Third, the company has plenty of growth potential. The beauty of its platform is that it’s really scalable. I see the company as well-placed to benefit from the retirement of the Baby Boomers (who love to travel).
Looking forward to 2023, we’re seeing strong demand in Q1, indicating that consumer confidence to travel remains high.
Airbnb 2022 results
Finally, the company is now profitable. This year, the group is projected to generate earnings per share of $3.30.
Now ,Airbnb shares are well off their 52-week highs. This time last year, they were trading near $165. Today, they’re near $110.
Yet even after this share price weakness, they’re still quite expensive. Currently, the forward-looking P/E ratio here is about 33. This adds risk to the investment case.
I’m convinced that buying now will pay off in the long run though. I think this travel company is just getting started.
